Paracelsian AndroVir for AIDS, AndroCar for cancer, planned for 1997 launches.
This article was originally published in The Tan Sheet
Executive Summary
PARACELSIAN ANDROVIR, ANDROCAR SUPPLEMENTS PLANNED FOR LAUNCH next March and July, respectively. AndroVir (PN355) is a potential treatment for HIV and cancer; AndroCar (PN27,1) is for cancer. Ithaca, N.Y.-based Paracelsian expects to introduce the two products as dietary supplements bearing claims such as "For a healthier immune system" for AndroVir or "To support a person's well-being" for AndroCar. FDA has objected in the past to immune strengthening claims for dietary supplements, including Pacific Biologic's claims for Resist ("The Tan Sheet" July 29, p. 8).